• About
  • Board
  • Expert Index
  • Podcasts
  • News
  • Sign up
  • Contact

Visit

VJHemOnc - Hematological Oncology
  • Home
  • Diseases
    Leukemia
    Lymphoma
    Multiple Myeloma
    Myeloproliferative Neoplasms
    Myelodysplastic Syndromes
    Others
    View all Diseases
  • Trials
    • MUK Nine b
    • TEAMM
    • MUK Seven
    • PERSPECTIVE
    • Hokusai VTE-Cancer Study
    • ZUMA-3
    • UKALL14
    • MEDI4736
    • BMS-936558
    • BRIGHT AML1019
    • View all trials
  • Medicines
    • Levofloxacin
    • Edoxaban
    • AMG 330
    • Glasdegib
    • IMGN779
    • Avapritinib
    • Cirmtuzumab
    • Pegfilgrastim
    • Procarbazine
    • Filanesib
    • View all medicines
  • Topics
    • Disease Biology
    • Pharmacy
    • Surgery
    • Treatment
    • Communication
    • Perspectives
    • Policy
    • Psycho-Oncology
    • Supportive Care
    • Transplantation
    • View all topics
  • Conferences
    • HOPA 2018
    • EBMT 2018
    • iwAL 2018
    • UKONS 2017
    • ASH 2017
    • MPN Advances Day 2017
    • NCRI 2017
    • ESH 2017
    • Myeloma 2017
    • BOPA 2017
    • View upcoming conferences
    • View previous conferences
  • Features
    • About
    • Board
    • Expert Index
    • Podcasts
    • News
    • Sign up
    • Contact
2:06
MURANO study: exciting times in CLL
George Follows
3:36
Retrospective multicenter analysis of venetoclax-treated CLL patients
Anthony Mato
4:01
Primary analysis of MURANO study data for R/R CLL
John Seymour
8:06
Combination Treatment with Two Targeted Agents Shows Promise in Previously Treated CLL
Peter Hillmen
1:00
Managing and predicting TLS in CLL patients
Peter Hillmen
3:09
BCL2 inhibition and CLL: the role of venetoclax
Peter Hillmen
5:52
The power of venetoclax
Claire Dearden
1:16
Preliminary results of ibruntinib in combination with FCR chemotherapy for CLL
Matthew Davids
0:45
The importance of considering a CLL patient’s tumor lysis risk status
Matthew Davids
1:06
Safety analysis of the BCL-2 inhibitor venetoclax for CLL
Matthew Davids
1:34
Why venetoclax is a promising new drug for CLL
Paolo Ghia
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Please enter your details if you would like to receive the latest Hemonc news and updates

Continue
Video channels
  • Chronic Lymphocytic Leukemia
  • Follicular Lymphoma
  • Multiple Myeloma
  • B-Cell Lymphoma
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Diffuse Large B-Cell Lymphoma
  • Chronic Myeloid Leukemia
  • Amyloidosis
  • Hodgkin Lymphoma
Join our community

Keep up-to-date via social media

Sign up for email updates

Get great new content delivered to your inbox

Sign up

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

The content of VJHemOnc is intended for healthcare professionals
  • Cookie Policy
  • Terms of Use
  • Terms of Use
  • Privacy Policy